Abec­ma sales dis­ap­point again as BC­MA com­pe­ti­tion ramps up, FDA ad­comm looms

Fourth-quar­ter US sales of Bris­tol My­ers Squibb’s BC­MA-tar­get­ing CAR-T ther­a­py Abec­ma last year de­clined by 40% com­pared to the same pe­ri­od in 2022, pri­mar­i­ly due …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER